Johnson & Johnson Begins Phase 3 Study of First Single-Shot COVID-19 Vaccine Candidate

Johnson & Johnson is beginning a final study to prove if a single-dose COVID-19 vaccine can protect against the virus. The study will be one of the world’s largest coronavirus vaccine studies so far, testing the shot in 60,000 volunteers in the U.S., South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. J&J’s vaccine is made with slightly different technology than others in late-stage testing, modeled on an Ebola vaccine the company created.

Source: Equities